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Abstract
Post-traumatic  nightmares  (PTNMs)  can  be  treatment  resistant  to  conventional
treatments for post-traumatic stress disorder (PTSD). New cognitive and behavioral
treatments  (CBTs)  for  nightmares  (NM)  and  pharmacological  treatments,  such  as
Prazosin, have been developed to directly reduce PTNMs. Objectives: The first objective
was to evaluate the impact of CBTs for NM and Prazosin on the reduction of PTNMs in
an adult population. A second aim was to explore the impact of these treatments in
general PTSD symptoms and sleep. Method: A systematic search of English and French
clinical studies on any CBTs and Prazosin treatments for PTNMs published from 1980
to 2012 was conducted in PsycINFO, MedLine, PILOTS,and ProQuest Dissertations and
Theses. Results: The final sample was composed of 26 studies. The combined effect size
(ES) for Prazosin was g = 1.30, 95% CI [0.61, 2.00], and for CBTs, it was g = 0.55, 95% CI
[0.38, 0.72]. Conclusions: Prazosin had a large impact on PTNM reduction, while CBTs
had a moderate impact. Specific NM treatments (Prazosin or CBTs) contribute to PTNM
reduction and reduce PTSD and sleep symptoms. These findings are significant to the
literature on PTSD and future studies should consider them. Several recommendations
are proposed.
Keywords: CBT, meta-analysis, nightmare, Prazosin, trauma
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1. Introduction
1.1. PTSD and nightmares
Nightmares (NM) are one of the intrusion symptom clusters of post-traumatic stress disorder
(PTSD) in the fifth edition Diagnostic and Statistical Manual of Mental Disorders (DSM-5) [1]. The
prevalence of frequent NM is 70% in individuals with PTSD compared to only 2–5% in the
general  population [2].  Post-traumatic  nightmares  (PTNMs)  are  different  from “normal”
dreams as they are recurrent frightening dreams of past traumatic events [3]. Their content
may vary from an exact replay to only some components of the trauma, such as changes in
time and place [3]. Another distinction is their role in PTSD. In the general population, sleep
loss impacts daily functioning due to fatigue and cognitive difficulties [4], leading to poor
quality of life [5]. However, in the particular PTSD context, the presence of NM seems to be
related to PTSD prevalence and severity [6], and therefore, to contribute to the development
of PTSD. They could even contribute to PTSD symptom maintenance [7].
PTSD used to be considered as an anxiety disorder in the fourth edition revised Diagnostic and
Statistical Manual of Mental Disorders (DSM-IV-TR) [8]. Now, it is part of the trauma- and
stressor-related disorders in the DSM-5 [1]. Several meta-analyses, systematic reviews, and
guidelines underline that general trauma-focused cognitive and behavioral treatments (CBTs)
(through exposure and cognitive restructuring) are superior, or equivalent, to other types of
psychological treatments, such as eye movement desensitization and reprocessing (EMDR),
psychodynamic psychotherapies, or supportive techniques (e.g., [9]). They also emphasize the
efficacy of selective serotonin reuptake inhibitors (SSRIs) as a pharmacological treatment [10].
However, studies also reveal that CBTs and SSRIs do not effectively resolve all PTSD symptoms
in individuals who no longer meet PTSD diagnosis criteria. In fact, NMs were found to be
treatment resistant, and residual insomnia was also reported [11, 12].
1.2. Emergence of treatments directly targeting nightmares
One approach is to conceptualize NMs in two steps after a traumatic event. First, right after
the trauma, NMs would be considered as trauma-induced and would be a PTSD symptom.
Later, at a second stage, they would become a learned behavior distinct from PTSD symptoms.
The idea is that the person, by fearing and avoiding NM content, cannot process the informa-
tion related to the event and cannot incorporate it [13]. As these NMs disrupt sleep, it can be
difficult for the victims to return to sleep and they may adopt unsuitable sleep hygiene, which
could lead to insomnia [14]. Therefore, new psychological and pharmacological treatments are
emerging and tested to directly reduce NMs.
Recently, the Standards of Practice Committee (SPC) of the American Academy of Sleep
Medicine (AASM) commissioned a task force to assess the literature on the treatment of NM
disorder in general. They presented their recommendations in a Best practice guide about
pharmacotherapies and CBTs for NM for adults [15, 16]. Their classification was based on study
designs from “level 1” (high-quality randomized clinical trials with narrow confidence
intervals) to “level 4” (case series or poor case-control studies or poor cohort studies or case
A Multidimensional Approach to Post-Traumatic Stress Disorder - from Theory to Practice206
reports). Their suggestions were made according to a level of recommendation from “level A”
(treatment recommended—level 1 or 2) to “level C” (treatments that may be considered—lever
3 or 4). Their recommendations concerned both psychological and pharmacological treat-
ments.
Regarding the medications conclusions, Prazosin was given an “A level recommendation”
compared to antidepressants, anxiolytics, anticonvulsants, and antipsychotics. Prazosin is an
α1-adrenergic receptor antagonist, which was first introduced as a treatment for high blood
pressure in 1970. It reduces the adrenergic response and has the advantage of crossing the
blood-brain barrier. We know that stimulation of α1 receptors induces the primitive fear
response, disrupts rapid eye movement (REM) sleep, and increases non-REM sleep. We believe
that Prazosin exerts its effect through a mechanism that blocks the primitive fear responses by
antagonizingthe α1 receptors in the CNS and decreasing PTNMs [17].
In addition, the Best practice guide lists six specific CBTs for NMs: imagery rehearsal therapy
(IRT) (Level A), systematic desensitization (Level B), lucid dreaming therapy (LDT) (Level C),
exposure, relaxation, and rescripting therapy (ERRT) (Level B), sleep dynamic therapy (Level
C), and self-exposure therapy (Level C). These CBTs conceptualize NMs as a learned behavior,
but each treatment approaches them differently. The IRT rationale is to select a repetitive NM,
to transform and write it into a new dream, and finally to rehearse it in imagination. The idea
is to gain control over the NM. The ERRT model is to expose the person to his original
nightmare content a little further than IRT. The participant has to write down his original NM
and to identify traumatic themes that will be used when rescripting and rehearsing it. Going
further than IRT, it also incorporates sleep hygiene education and modification, and relaxation
for insomnia. Contrary to IRT and ERRT, LDT will train individuals to become aware that they
are dreaming while they are actually dreaming and to change the scenario [18].
1.3. Objectives
The first objective of this chapter is to review and evaluate the impact of CBTs compared to
Prazosin for NM reduction, after a traumatic event in an adult population. The secondary
objective is to evaluate the impact of both types of interventions on other PTSD symptoms and
sleep.
2. Method
2.1. Search strategy
Studies published from 1980 (with the introduction of PTSD in the DSM-III) to the end of
December 2012 were identified by searching the electronic databases MedLine, PsycINFO,
PILOTS, and ProQuest Dissertations and theses databases [19] to identify relevant studies
evaluating the impact of CBT and Prazosin on PTNMs in an adult population. Each search was
separately run using the following command in all fields: (treatment OR therapy OR Prazosin
OR cognitive OR behav* OR CBT) AND (nightmare* OR dream*) with the asterisk specifying
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the plural and grammatical variations. We also scanned reference lists of relevant meta-
analyses, systematic reviews, and reference lists of each study included in this meta-analysis.
2.2. Eligibility criteria
To be included in the meta-analysis, studies must have met the following criteria: (a) they
reported quantitative treatment outcomes for NMs (such as frequencies or questionnaires’
scores) occurring after a traumatic event; (b) at least one group received CBT or Prazosin
treatment for NM; (c) the study either had a group protocol or was a case study of at least three
participants; (d) the participants were 18 years old and above; (e) all the participants presented
PTSD symptoms (evaluated by validated questionnaires or by a clinical and structured
interview) and PTNM complaints; (f) the study was published between 1980 and 2012; and (g)
the study was published in English or in French. Studies were excluded if they were (a)
abstracts of posters and (b) did not report original results.
2.3. Data extraction
Information was extracted from each eligible record using a data extraction sheet adapted from
previous meta-analyses [11, 20]. Data extracted were : (i) study identification (e.g., authors and
publication date); (ii) study description (e.g., protocol sampling, assignment of participants,
and research reports following CONSORT statement for randomized studies [21]); (iii) sample
characteristics (i.e., sample size, gender, mean age and standard deviation, PTSD and acute
stress disorder (ASD) diagnoses, records of PTSD treatments, trauma type, trauma date of
occurrence, nightmare definition, nightmare frequency, nightmare intensity, nightmare
content, explicit report of sleep difficulties other than nightmares, reports of comorbidity, and
attrition rate); and (iv) the type of intervention for NMs at large was also reported (i.e., IRT,
IRET, ERRT, LDT, relaxation, exposition, desensitization, EMDR, Prazosin, and any other CBTs
for NMs). CBTs for NMs were defined as incorporating cognitive (new dream rehearsal,
restructuration, etc.) and/or behavioral strategies (progressive muscle relaxation, gradual
exposure, etc.), contrasting with other approaches, such as dream interpretation. We recorded
the number of therapy sessions, duration, the therapy modality (i.e., individual psychotherapy,
in groups, at distance with or without any contact), the presence of a therapy protocol, the
therapist’s training (psychologist, graduates in psychology, other medical professionals, other),
and whether the CBT treatment also targeted PTSD and insomnia problems in addition to
NMs. For Prazosin studies, trade names of Prazosin (Minipress, Vasoflex, Pressin, and
Hypovase) were considered in the study screening and we extracted the average prescription
(in mg/day), the timing of the prescription, the presence of a protocol for the prescription, and
the presence of a washout period at follow-up. (v) In addition, the type of NMs, PTSD and
insomnia outcome and measures were coded as either (a) clinic interview, (b) daily self-
monitory, (c) EEG for NMs and insomnia, (d) validated questionnaires, (e) subscales from
questionnaires, (f) isolated items from questionnaires or interviews, or (g) survey. And, finally,
(vi) information was gathered to calculate the following three types of effect sizes: group
comparison on post-treatment data (between-group analysis), pre- vs. post-treatment data for
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groups receiving CBT or Prazosin (within group-group analysis), and pre- vs. post-treatment
data for control groups.
2.4. Inter-rater agreement
In order to evaluate inter-rater reliability and to control for data extraction bias, each study
was systematically checked by pairs of independent reviewers. Their results were compared
and any disagreements were resolved by discussion. Before beginning the coding process, the
rating instrument was tested with the four raters going through the coding form and checking
one article testing CBT and one trial studying Prazosin together. Judges were students enrolled
in a PhD program in psychology. The inter-rater reliability was good and varied from 58.3%
to 100%. The strongest agreements were related to sampling method and treatment type while
the lowest referred to attrition and female percentages, which may reveal inconsistencies in
reporting. The final sample was composed of 26 studies published in English: 8 studies on
Prazosin [22–29] and 18 studies on CBT for NM [6, 30–46] (Figure 1).
Figure 1. Search strategy flowchart.
The Impact of Cognitive-Behavioral Therapies for Nightmares and Prazosin on the Reduction of Post-Traumatic...
http://dx.doi.org/10.5772/64224
209
2.5. Data analyses
The meta-analyses were performed using the random-effects model [47]. The analyses were
conducted with Comprehensive Meta-Analysis (Version 2) [48]. Effect sizes (ES) were computed
with Hedges’ g between groups using mean and standard deviation (SD) [47] except for one
study where they were obtained from t values [37]. When available, quantitative analyses
were performed on the difference between the experimental and control groups at post-
treatment (between-group); otherwise analyses were computed on pre- and post-data for the
same group (within-group). As in the last case, the correlation coefficient r between pre- and
post-test for each data is needed, and as this information was missing, r was set to 0 in order
to be conservative and to give to these studies the smallest and the same weight, so there
will be no bias in weighting [47]. However, we executed sensitivity analysis using a range of
plausible correlations (0; 0.5 and 0.95) and the results did not significantly differ between
each correlation. The direction of the ES was set as positive when NMs, PTSD symptoms,
and sleep variables were improved at post-treatment or for the experimental compared to
the control group at post-treatment. ES were not computed at follow-up due to disparities in
reporting these data for CBT studies, and only one Prazosin study provided them.
For the NMs variable, effect sizes were calculated based on means and SD of weekly NM
frequency for CBT studies; and on the CAPS-B2 final scores (item B2 on the Clinician Admin-
istered PTSD Scale) for Prazosin studies. The CAPS-B2 item sums up the frequency and the
intensity (from 0 to 4) of recurrent distressing dreams related to the traumatic event (refer to
Blake et al. [49] for a scale description). When these NMs were reported by month or by night,
we computed their mean by the week. Effect sizes were also computed for PTSD symptoms.
For CBTs, we considered any questionnaire evaluating the construct of PTSD symptoms
intensity: impact of event scale (IES-R [50]), PTSD Checklist—Civilian and Military Versions (PCL
[51]), post-traumatic symptom scale (PSS [52]), and post-traumatic diagnostic scale (PDS [53]). For
Prazosin, we used the scores of the PCL and the CAPS. Finally, ES were calculated for sleep
difficulties using (1) the CAPS-D1 (CAPS, item D1) final score (sum of the frequency and
intensity) for Prazosin and (2) scores on the Pittsburgh Sleep Quality Index (PSQI) [54] for CBTs.
Computations were also possible for the insomnia construct, as data Pertained only to CBT
studies, using scores on the Sleep Impairment Index (SII [55]).
We used the data, if available, on an intent-to-treat basis (patients who were enrolled and
randomly allocated to treatment), otherwise variables were selected on a completer basis. Also,
as a few study designs did not implement immediate post-evaluation and rather evaluated the
interventions at follow-up, we decided to include them in the analysis if follow-ups were less
than three months after the end of the treatment. Each effect size (and the combined effect size)
was calculated with 95% confidence intervals.
We tested for heterogeneity with the Q test and the proportion of true variance was assessed
with the I2 index for each computed ES. Q tests were also used for contrast analyses. Also, due
to problems of power in this meta-analysis (less than 20 studies) (n = 8 for Prazosin; n = 18 for
CBT studies), we computed the 95% confidence intervals (95% CI) for the I2 index [56, 57].
Heterogeneity was detected when Q test was significant (p < 0.05) or I2 index was higher than
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50% [56]. In this case, sensitivity analyses and ES comparison across subgroups (subgroup
analyses) were performed using the random effect model. Finally, to test for possible publica-
tion biases, funnel plots evaluating the association between the Hedges’ g and the standard
error were visually assessed [58]. In addition, Orwin fail-safe N tests [59] were computed to
estimate the number of studies with no effect necessary to reduce the combined ES to a
clinically nonsignificant value (0.2).
3. Results
3.1. Characteristics of the studies
Three Prazosin and 10 CBT studies used between-group comparison and randomization to
assign participants except for one Prazosin study. However, no randomized Studies specified
when they fulfilled CONSORT criteria [21]. Their comparison groups were placebo treatment,
waiting list, or no active treatment. All studies used a convenience population sample. Eight
Prazosin and 13 CBT studies had immediate post-evaluation. Only one Prazosin and 11 CBT
studies reported data at follow-up.
Author, year  Mean dosage achieved
(mg/day)(SD) 
Time of prescription
(in weeks) 
Procedure for
dosage 
Tapering
mentioned 
Boynton et al., 2009  2.30 (1.40)  8  Yes  – 
Calohan et al., 2010  4.10 (2.20)  –  Yes  No 
Peskind et al., 2003  2.30 (0.70)  8  Yes  No 
Raskind et al., 2002  9.60 (0.90)  8  Yes  No 
Raskind et al., 2003  9.50 (0.50)  9  Yes  Yes 
Raskind et al., 2007  13.30 (3.00)  8  Yes  No 
Taylor et al., 2008  3.10 (1.30)  3  Yes  Yes 
Thompson et al., 2008 9.60 (6.00)  –  Yes  – 
Table 1. Treatment characteristics for Prazosin studies.
There was a large variation in the total sample sizes from n = 9 to n = 51, or a total of 181
participants for Prazosin studies; and a variation from n = 4 to n = 278 for CBTs, or a total of
1169 participants. We also observed a variation in female proportions: from 0% to 84.62% in
Prazosin treatments, and from 0% to 100 % in CBTs. Mean ages varied from M = 26.69 to M =
76.00 for Prazosin, and M = 36.17 to M = 59.42 for CBTs. The attrition rates varied from 0% to
40% for Prazosin and from 0% to 53.85% for CBTs. The percentage of participants who did
not finish the treatment did not differ by type of treatment (Prazosin or CBT) (p = 0.08). The
first most common trauma for both types of studies was combat experience, followed by
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sexual assault and mixed trauma. No studies recorded medical comorbidities. To evaluate
the impact of Prazosin on PTSD symptoms, only two studies reported global score for PTSD
questionnaires. CBTs studies mainly used questionnaires related to PTSD symptom intensity
(such as the PTSD Checklist Civilian Version). Finally, four Prazosin studies used the CAPS
and more precisely its item D1 for sleep disturbance related to PTSD, and one study used
the PSQI to evaluate sleep quality at large.
Author, year  Type of
CBT 
No. of
sessions 
Mean
duration
(min) 
Delivery  Therapists PTSD
addressed 
Insomnia
addressed 
Cook et al.,
2010
IRT 6 90 GROUP  PSY
 and
 OTHER
No No
Davis & Wright,
2005b
ERRT 3 120 GROUP  – No Yes
Davis & Wright,
2007
ERRT 3 120 IND/GROUP – No Yes
Davis et al.,
2011
ERRT 3 120 IND/GROUP – No Yes
Forbes et al.,
2001
IRT 6 90 GROUP  PSY No No
Germain &Nielsen,
2003
IRT 1 180 GROUP  – No No
Germain et al.,
2012
IRT 8 45 IND  STU No Yes
Gerlinde C.
Harb et al.,
2009
IRT 7.5 – IND  PSY
 and
 OTHER
No Yes
Krakow,
Johnston,
et al., 2001
IRT 3 200 GROUP  OTHER No Yes
Krakow et al.,
2000
IRT 3 140 GROUP  – No No
Krakow, Hollifield,
et al., 2001
IRT 3 140 GROUP  OTHER No Yes
Lancee
et al.,
2010
IRT/IRT+
SH/IRT
+SH+LDT
– – REMOTE  – No NA
Lu
et al.,
2009
IRT 6 90 GROUP  PSY
 and
 OTHER
No –
Nappi
et al.,
2010
IRT 5 90 IND/GROUP SPY
 and
 STU
No No
Pruiksma,
2011
ERRT 3 105 IND/GROUP SPY
 and
 STU
No Yes
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Author, year  Type of
CBT 
No. of
sessions 
Mean
duration
(min) 
Delivery  Therapists PTSD
addressed 
Insomnia
addressed 
Swanson
et al.,
2009
ERRT 10 90 GROUP  PSY No Yes
Thunker
&
Pietrowsky,
2012
IRT 8 50 –  – No No
Ulmer
et al.,
2011
IRT 6 60 IND  PSY No Yes
Note. ERRT: exposure, relaxation and rescripting therapy; IRT: imagery rehearsal therapy; LDT: lucid dreaming
therapy; OTHER: other professions (e.g., nurse, physician); NA: not applicable; PSY: psychologist; SH: sleep hygiene;
STU: graduate student in psychology; REMOTE: treatment administered remotely (e.g., mail, Internet, video).
Table 2. Characteristics of CBT studies.
Tables 1 and 2, respectively, present treatment characteristics for Prazosin and CBT studies.
In Table 1, the mean dosage of Prazosin varies from M = 2.30 to M = 13.30 mg/day with a
time of prescription ranging from three to nine weeks. All studies provided a procedure to
initiate a stable Prazosin dosage but only two studies described a tapering process.
In Table 2, 13 studies looked at IRT efficacy, 5 at ERRT, 1 at IRT incorporating sleep hygiene
(SH), and another at IRT incorporating SH and LDT. The mean number of sessions was 5 (from
1 session to 10 sessions), and they lasted from 45 to 140 minutes. They were mainly delivered
in a group format by a psychologist. None of the therapies directly addressed PTSD, but half
of them specifically addressed insomnia (since the ERRT protocol automatically incorporates
the reduction of bad sleep habits).
Regarding NM definitions employed in each study, we noticed that all Prazosin studies used
the DSM-IV-TR definition based on the CAPS-B2. It contrasts with CBT studies where they
varied between articles, some applying the DSM-IV-TR definition, their own definition, or not
providing one. Concerning NM frequency as an inclusion criterion, Prazosin studies employed
the CAPS-B2 with a cutoff varying from three to six out of eight. For CBT studies, the criterion
used most often was at least one NM per week in the last month or in the last six months.
Finally, concerning NM content, as Prazosin studies referred to the CAPS-B2, NMs were related
to trauma but it was not specified if they were a replica of the event or only trauma-related. In
CBT studies, a few authors gave this information, as in Cook et al. [30] where NM were replica
or in Forbes et al. [34] with only trauma-related NM.
3.2. Effect size summary on PTNMs
ES for Prazosin evaluated by the CAPS-B2 (weekly PTNMs in the last month) varied from a
small effect (0.28) to a large effect (3.91) (see Figure 2). The combined ES was to g = 1.30, 95%
CI [0.61, 2.00], which indicates a significant large effect (Z = 3.66, p < 0.001). There was signif-
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icant heterogeneity in ES across samples (Q (6) = 21.38, p < 0.001) and a significant 72% of the
total variability among ES indicates that the inconsistency between studies is high (I2 = 71.93,
95% CI [39.21, 87.04]).
Initially, ES was computed with one additional study [25]. After an outcome sensitivity
analysis, homogeneity appeared to be affected by the result of this specific study, which also
conflicted with the rest of the studies. We, therefore, decided to compute Prazosin combined
ES without it.
Regarding subgroup analyses (group comparison and mean dosage subgroups), no significant
differences were found. However, the small number of studies and, therefore, the loss of power
could explain nonsignificant heterogeneity within each subgroup [56] while differences could
be observed (e.g.,“under 5 mg,” vs. “between 5 and 10 mg”).
Figure 2. Results of meta-analysis for Prazosin studies using the CAPS-B2 and under the Random-effect model.
Figure 3 reports the ES summary for CBT studies on weekly PTNM frequency. We noticed ES
varied from a small effect (0.07) to a large effect (1.75). The combined ES was g = 0.55, 95% CI
[0.38, 0.72], which indicates a significant moderate effect size for CBTs on weekly PTNM
frequency (Z = 6.21 p < 0.001). There was significant heterogeneity in ES across samples (Q (19)
= 35.26, p < 0.05) with a moderate amount of observed heterogeneity (46%). The inconsistency
between studies was moderately high (I2 = 46.12). Subgroup analyses did not reveal any
statistical differences between studies. As mentioned before, this result may be due to loss of
power rather than to homogeneity alone.
3.3. Secondary effect size summary
Concerning the PTSD symptoms, the ES for three studies varied from a small effect (0.27) to a
large effect (0.88). Their combined ES was g = 0.58, 95% CI [0.12, 1.04] and was significant for
CBT on PTSD symptoms (Z = 2.45, p < 0.05). The analysis found homogeneity in ES across
samples (Q (2) = 1.18, p = 0.55). The amount of observed heterogeneity was null (0%), and
therefore, there was no inconsistency between the studies (I2 = 0.00).
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For the PSQI variable, ES varied from a medium effect (0.71) to a large effect (0.98). The
combined ES was g = 0.83, 95% CI [0.32, 1.35], which indicates a significant and large effect of
Prazosin treatment on sleep quality (Z = 3.16, p < 0.05). There was nonsignificant heterogeneity
in ES across samples (Q (1) = 0.30, p = 0.58). The amount of observed heterogeneity was null
(0%), and therefore, there was no inconsistency between the studies (I2 = 0.00).
Regarding the CAPS-D1 variable, ES varied from a medium effect (0.48) to a large effect (1.74).
The combined ES was g = 1.26, 95% CI [0.62, 1.89], indicating a significant large effect of Prazosin
on PTSD sleep difficulties (Z = 3.88, p < 0.001). There was nonsignificant heterogeneity in ES
across samples (Q (3) = 5.59, p = 0.133). The amount of observed heterogeneity was moderate
(46%) and confirmed that inconsistency between studies was moderately large (I2 = 46.36).
The impact of CBTs on the intensity of PTSD symptoms varied from small ES (0.02) to large
ES (1.46). The combined ES in 16 studies was g = 0.59, 95% CI [0.38, 0.80], which indicates a
significant large effect (Z = 5.47, p < 0.001). There was significant heterogeneity between
studies (Q (15) = 35.24, p < 0.05) and a significant 57% of the total of the variance among ES
indicates that inconsistency between studies was moderately large (I2 = 57.43). Subgroup
analyses did not reveal any statistical differences between them. Previously, the amount of the
observed heterogeneity was higher (75%) and could be related to high heterogeneity across
studies (I2 = 74.68). There was also a significant heterogeneity in ES across samples (Q (16) =
63.19, p < 0.001). ES varied from small ES (0.02) to large (5.70) and the combined ES across 17
studies was g = 0.69, 95% CI [0.42, 0.97], which indicated a significant moderate effect for CBTs
(Z = 4.96, p < 0.001). Therefore, an outcome sensitivity analysis between studies was performed.
Homogeneity was affected by the result of the Ulmer et al.’s study (2011) [46], which conflicts
(5.70) with the rest of the studies and we therefore decided to compute the combined ES
without this study.
Figure 3. Results of meta-analysis for CBT studies on weekly NM frequency and under the Random-effect model.
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Concerning the impact on PSQI outcome, ES varied from 0.07 to 4.63. The combined ES
computed for 14 studies was g = 0.95, 95% CI [0.56, 1.34], which indicated a significant large
CBT effect (Z = 4.78 p < 0.001). There was significant heterogeneity in ES across samples (Q (13)
= 66.27, p < 0.001). The amount of observed heterogeneity was high (80%) and can be associated
with true variance across studies (I2 = 80.39). Therefore, an outcome sensitivity analysis
between studies was performed and no studies appeared to influence heterogeneity. No
statistical differences between subgroup analyses were found, except for the subgroup
insomnia, which was marginally significant with Q (1) = 3.39, p = 0.07. It appeared that the
addition of one sleep management component has a better effect on PSQI.
Another impact on sleep is insomnia where ES varied from 0.72 to 1.77. The combined ES,
computed for six studies, was g = 1.06, 95% CI [0.78, 1.34], which represents a significant large
effect of CBTs (Z = 7.41, p < 0.001). There was no significant heterogeneity in ES across samples
(Q (5) = 2.69, p = 0.75). The amount of observed heterogeneity was null (0%), and therefore,
there was no inconsistency between the studies (I2 = 0.00).
3.4. Publication bias
The shapes of the funnel plots of Prazosin outcomes (CAPS-B2, PTSD symptoms, and CAPS-
D1) gave some indications of publication bias. The Orwin fail-safe test revealed that 27 studies
for CAPS-B2, 6 studies for PTSD symptoms, and 20 studies for CAPS-D1 with a null effect
should theoretically be added to the analysis to obtain a combined ES of 0.2. The funnel plots
did not reveal any publication biases, and the Orwin fail-safe test results were large for CAPS-
B2 and CAPS-D1. Therefore,the results from these two outcomes in this meta-analysis are valid
and publication biases are negligible. However, caution is advised when interpreting the
results for PTSD symptoms, given that six studies are sufficient to invalidate the analyses. Also,
it was not possible to run publication bias analyses for PSQI, as we only had two studies.
The funnel plot shapes for CBTs indicated a limited effect of publication bias on the results.
Also, Orwin fail-safe test results were 30 for weekly NM frequency, 30 for PTSD intensity, 43
for PSQI, and 26 for insomnia measure. As the funnel plots did not reveal any publication
biases, and the Orwin fail-safe test results were large, we therefore concluded that CBT results
from this meta-analysis are valid and publication biases are negligible.
4. Discussion
4.1. Search results
Fifty-one studies considered treatments specifically targeting PTNMs in an adult population,
and 26 studies reported data and were, therefore, included in this meta-analysis. Out of eight
Prazosin studies, only three reported data on PTSD symptoms, two on sleep difficulties (using
the PSQI), and four on insomnia (using the CAPS-D1). Of the 18 CBTs, 17 reported data on
PTSD symptoms, 14 on sleep difficulties with the PSQI, and 6 on insomnia (using the ISI and
SII). We also noticed a tendency for ERRT, IRT, or Prazosin studies to be conducted by the same
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research teams [27, 40, 60]. In fact, five out of eight teams working on Prazosin effect were from
the University of Washington in Seattle. Of the 18 CBT studies for nightmares, 4 were issued
from the University of Tulsa and 2 from the University of Philadelphia. Also, these studies
were mostly published after 2000. This small number of studies is not surprising, as PTSD
study in psychology and in PTNM research is quite new. It was only in 1980, PTSD was
introduced in the DSM-III, and only in 1989 that Ross et al. [61] presented the hypothesis that
“sleep disturbances are the hallmark of PTSD,” which opened the study of PTNMs. Also,
PTNMs are conceptualized as one of the intrusive symptoms of PTSD [3], and therefore, as a
secondary symptom of PTSD. In the dreaming field, they are seen as an adaptive function to
emotionally adjust to trauma. This main discrepancy hinders their introduction in PTSD
treatment and slows down and complicates their inclusion in research. Besides, recommen-
dations concerning NM treatments were only published in 2010 [15], and the first reported
open-label study of Prazosin for PTNM treatment was conducted in 2000 [62].
4.2. Treatment efficacy
Looking at the positive results of the impact of Prazosin (g = 1.30) and CBTs (g = 0.55) on PTNM
reduction, we found that treatments specifically targeting NMs are efficient. It was not possible
to directly compare CBTs for NMs to Prazosin, but considering the large ES for Prazosin, we
may conclude its efficacy is superior to CBTs for NMs in the reduction of PTNMs at post-
treatment. However, several considerations on the overall efficacy of each treatment need to
be examined and caution in confirming the superiority of Prazosin over CBT is advised.
First of all, only one study [36] has compared both treatments with a placebo group at short
and long terms. Prazosin demonstrated slightly better results than CBTs. However, authors
reported that their results did not differ at the four-month follow-up assessment.
Another consideration is that most medications have side effects that may force participants
to withdraw from one treatment [63]. From a few Prazosin studies, we know researchers
sometimes had to stop its administration due to adverse effects, such as dizziness [22], nausea
and headache [23], and fainting and nasal congestion [64]. Nevertheless, attrition rates did not
statistically differ from Prazosin treatment (0–40.00%) to CBT (0–54.31%). Also, CBT can also
present side effects as costs, stigma, etc., but no information was provided. This aspect should
therefore be considered in the future for both types of treatments.
Also, the majority of Prazosin studies did not report data at follow-up. It seems the authors’
first objectives were to determine the optimal dose to be NM free. It is therefore impossible to
evaluate the rate of relapse after stopping this treatment, whereas CBTs reported data at follow-
up. In Raskind et al. [26], the authors mentioned that Prazosin effect did not persist after its
cessation in a few patients, who returned to their initial NM frequency. This observation
reminds us of the broader issue of medications benefits compared to psychological treatments
in PTSD [63].
Another concern is related to the characteristics of the studies, which could have influenced
the computed combined ES for both types of treatments. First, we noticed large variations in
the sample sizes, with a total of 181 participants for Prazosin (from n = 9 to n = 51) and 1169
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participants for CBTs (from n = 4 to n = 278). In addition, the evaluation of NMs varied between
the two types of treatments (CAPS-B2 versus self-reported questionnaires). Moreover,
Prazosin effect seems to vary according to its mean dosage, as the effect of a “small” dosage
(“under 5 mg,”g = 1.57) was equivalent or even more efficient than a higher dosage (“between
5 and 10 mg,”g = 1.30; “over 10 mg,” g = 0.81) (without reaching a statistically significant
difference). On the other hand, some CBT studies did not favor immediate postevaluation and
only reported data at follow-up (e.g., [30]).
When analyzing the efficacy of CBTs for NMs, we noticed that variations in their formats
(individual compared to group format) or in the type of treatment (ERRT compared to IRT)
could influence their impact. For example, even if subgroup analyses did not show any
statistical differences, subgroup ES for individual CBT was higher (g = 0.87) than the other
types of formats. Also, treatment efficacy varied according to the type of CBT, with a slightly
higher ES subgroup for ERRT (g = 0.70) over IRT (g = 0.56). To date, only a few studies have
looked at the therapeutic ingredients for these two CBTs, and it would be interesting to directly
compare them in the future.
Finally, to attain our second objective, we underlined that the efficacy of these two treatments
was not limited to PTNMs and extended to other symptoms. Their impacts were positive and
equivalent for PTSD symptoms (g = 0.58 for Prazosin; g = 0.59 for CBTs), for the PSQI (g = 0.83
for Prazosin; g = 0.95 for CBTs), and for sleep in general (g = 1.25 for Prazosin; g = 1.06 for CBTs).
No subgroup analysis achieved statistical significance except for the subgroup looking at the
efficacy of incorporating a sleep management component, which was marginally statistically
significant for the PSQI. This result means therapists or researchers should therefore consider
adding this component to IRT or to enhance it in ERRT.
As mentioned before, caution is advised in interpreting these results as discrepancies remained
with the type of questionnaires selected. Nevertheless, these secondary effects of treatments
specifically targeting NMs are interesting. Even if previous ESs are moderate or high, they are
similar to those published in Belleville et al. [20]. The author pointed out that CBT for insomnia
had a moderate impact on anxiety in individuals who presented insomnia, with or without a
comorbid anxiety disorder. In the case of PTSD, it is therefore important to evaluate the impact
of Prazosin and CBTs for NMs on PTSD.
4.3. Implication of results
The large ESs obtained for Prazosin and CBTs demonstrate to clinicians the relevance of using
specific NM treatments. From a research point of view, these positive results emphasize the
idea that PTNM could become an independent disorder rather than a PTSD symptom that
should disappear with conventional CBT or medications. Therefore, it requires a specific
treatment, and studies in the PTSD field should focus more on sleep. Moreover, a limited
update of the literature search was performed since December 2012, four articles [65–68] were
published, as well as new meta-analysis and systematic reviews [69, 70], and still support the
present results.
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Prazosin, as a medication and because it is linked to PTSD biology and to the neurobiological,
correlates between PTSD symptoms and sleep and presents several advantages compared to
psychological treatments. First, it seems to offer the possibility of treating nightmares without
considering their content compared to CBTs for NM. It represents an interesting option for
some patients, for example, when therapy is not available (e.g., soldiers who are still on duty)
[63]. It can also have a positive impact on the other PTSD symptoms; and finally, its low cost
makes it a promising pharmacological option. However, it seems to take most of the time eight
weeks prescription to obtain positive result while observing only one CBT session can be
sufficient to train a patient to get rid of his nightmares. Moreover, no standard for Prazosin
administration and duration exists.
On the other hand, psychological treatments help to deal with frightening content of NM. It
is theoretically believed that CBTs for NM repair the normal sleep process which has been
disrupted by NM. In fact, one sleep function is to select, classify, and consolidate information
and the emotions lived during the day in the long-term memory [71]. When this process is
interrupted by NM because of a strong emotion, the integration of new memories is impeded.
In PTSD, individuals live negative emotions during PTNM, and the incorporation of the
information related to the traumatic event fails [72, 73]. Compared to Prazosin, the main
advantages of ERRT and IRT are easy and rapid learning (sometimes in one session), of how
to eliminate NM. But their main disadvantage is that no standards have been proposed to
deliver them, and research needs to be conducted for different types of trauma, different types
of NM content, and different participant characteristics (such as gender).
4.4. Strength and limitations
Studies may not be exactly the same or perfect. Disparities remained as the two treatments
diverge clinically and methodologically, and therefore, heterogeneity had to be expected.
However, analyses reflected that no bias could be detected. Nevertheless, caution should be
exercised in the interpretation of the efficacy of Prazosin for PTSD symptoms. First, it was not
possible to directly compare Prazosin against CBTs for PTNMs. Also, no information was
provided on therapeutic maintenance. We observed variations in CBTs format and Prazosin
administration. Methodological limits were detected due to a lack of questionnaire standard-
ization to evaluate PTNMs; and NM definitions or NM content were not reported.Finally,
variations in the population (sex and age) and in sample sizes were also observed.
There are some limitations including experimental and quasi experimental studies in this
meta-analysis as in the latter case, the treatment and control groups may not be comparable at
baseline. However, several strategies were used to increase the validity of our results: (1)
reviewing each study to carefully interpret our results; (2) grouping outcome by type of
questionnaire evaluating the same construct; (3) ES analyses within subgroups was a way of
investigating variations; and (4) deciding upon inclusion criteria ahead of the review process
and reporting them in a protocol. In spite of all these precautions, a larger N, more particularly
for Prazosin, would have increased the statistical power of our analysis and would have helped
us to highlight interesting results within subgroup analyses. Therefore, the combined ES
reported are valid. Also, the “file drawer problem” criticism can be ignored for CBT studies
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and should be interpreted with caution for Prazosin studies, more particularly for the PTSD
symptom variable [47].
Finally, systematic reviews and meta-analysis have previously been published on these new
psychological treatments and on Prazosin (e.g., [17, 74–78]). The main advantages of the
present study are, compared to the previous ones, to have screened studies written in English
and French and to have considered randomized and nonrandomized studies. Also, if looked
at all types of nightmares, treatments not only considered imagery rehearsal treatments, in an
adult population with PTSD evaluated by validated questionnaires or structured interviews.
At last, this study combined both a meta-analysis and a systematic review on CBT for night-
mares and Prazosin, which allowed discussing their respective impacts and advantages.
4.5. Further studies
Despite the contribution of this study, future trials should consider some of the weaknesses
observed in this meta-analysis when NM is in a PTSD context. First, efforts should be made to
standardize the methodology used by including a control group, reporting outcomes at follow-
ups, and giving NM definition or content.
Also, the different methods used to evaluate NM frequency in this meta-analysis emphasized
that standardization was needed for questionnaire administration, NM definition, and
treatment format. In fact, we observed that all Prazosin studies used the CAPS, a retrospective
measure to evaluate NM, while CBTs used both self-reported retrospective and prospective
measures like home daily logs. More precisely, all Prazosin studies evaluated NM using the
CAPS-B2 item, compared to CBTs, which retrieved items evaluating NM from various
retrospective questionnaires or home sleep logs. Only two studies, by the same author [36,
79], included objective sleep measurements (polysomnography, PSG). To date, prospective
daily logs are considered the gold standard for the measurement of NM frequency [80], as self-
reports underestimate current NM frequency [81]. Therefore, results could differ according to
the method of measurement used and caution is advised in evaluating to Prazosin impact.
Only a few studies specified NM definition. Even if most studies adhered to a frequency cutoff
of one weekly nightmare minimum or an average of two or more NM per week, it is not clear
what participants understood by NM. In Prazosin studies, the CAPS-B2 item refers to the
frequency and the intensity of recurrent distressing dreams related to the traumatic event.
Therefore, we could wonder if the impact of Prazosin was on NM frequency or on NM distress.
This could influence the interpretation of results. In addition, we could not retrieve information
regarding NM content. As we know, PTNMs may be trauma-related or replicative trauma [3].
Therefore, it would have been interesting to have access to this information in order to evaluate
which kind of PTNM contents was targeted and by which CBT. In fact, each treatment has its
own rationale and degree of exposure to the selected NM. Therefore, this information would
be an indicator of which PTNM contents favor each treatment and could help to refine
guidelines.
Disparities were also observed in sample characteristics, with women being less represented
than men, more particularly in Prazosin studies; and with combat experience and sexual
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assaults being the main considered trauma. Research in the PTSD field is closely linked to war
history but it is also important to consider other types of trauma. We could wonder, for instance,
if one of the CBTs for NM would be more adapted according to the type of trauma (i.e., PTNM
content being different in each case). This will help to generalize the results and to provide
guidelines to clinicians in choosing which treatment to apply in a specific situation.
Recommendations on treatment delivery should be proposed (mean dosage, no. of sessions,
and NM content) in order to help clinicians and to allow comparison between studies. This
meta-analysis raises the possibility to directly treat PTNMs, as a symptom of PTSD, but clinical
aspects should be examined. Can we combine any treatment for PTSD with any treatment for
PTNMs? Which treatment should be prioritized in complicated PTSD? Could we add Prazosin
at any moment in the treatment? Which treatment for PTNMs will be more appropriate in
function of individual characteristics (such as gender or type of trauma)? Could we incorporate
specific NM treatments in a conventional CBT for PTSD? Many avenues are opened to those
who want to participate in standard PTSD treatment improvement.
Finally, secondary measures, such as PTSD scores and sleep, should be recorded.
5. Conclusions
We know CBTs and SSRIs do not effectively resolve all PTSD symptoms, as nightmares were
found to be treatment resistant and residual insomnia was reported. From the positive results
of this meta-analysis, we know specific NM treatments (Prazosin or CBTs) contribute to NM
reduction. These treatments also demonstrate PTSD and sleep symptom reduction. The overall
conclusion of this meta-analysis is that treating NM with Prazosin or CBTs directly is
interesting and can be a way to improve conventional CBTs for PTSD. However, no consensus
or guidelines are available to treat PTNMs. From these outcomes, clinicians can conclude that
NM can affect the efficacy of first-line PTSD treatments, and new treatments are developed to
solve this problem, while in sleep research PTSD outcomes should be reported.
Author details
Katia Levrier1, Carolyn Leathead1, Delphine-Émilie Bourdon1, Sophie Lacerte1,
André Marchand1* and Geneviève Belleville2
*Address all correspondence to: marchand.andre@uqam.ca
1 Department of Psychology, Université of Quebec in Montreal, Montreal, Canada
2 Université Laval, Québec, Canada
The Impact of Cognitive-Behavioral Therapies for Nightmares and Prazosin on the Reduction of Post-Traumatic...
http://dx.doi.org/10.5772/64224
221
References
[1] American Psychiatric Association. (2013). Diagnostic and statistical manual of mental
disorders (5th ed.). Arlington, VA: American Psychiatric Publishing.
[2] Lancee, J., et al., A systematic review of cognitive-behavioral treatment for nightmares:
toward a well-established treatment. J Clin Sleep Med, 2008. 4(5): p. 475-80.
[3] Phelps, A., D. Forbes, and M. Creamer, Understanding posttraumatic nightmares: an
empirical and conceptual review. Clin Psychol Rev, 2008. 28(2): 338–355.
[4] Walker, M.P., Cognitive consequences of sleep and sleep loss. Sleep Med, 2008. 9(Suppl.
1): S29–S34.
[5] Caldwell, B.A. and N. Redeker, Sleep and trauma: an overview. Issues Mental Health
Nursing, 2005. 26(7): 721–738.
[6] Pruiksma, K.M.E., A randomized controlled trial of exposure, relaxation, and rescript-
ing therapy and relaxation training for chronic nightmares in trauma-exposed persons:
findings at one week posttreatment, University of Tulsa, Tulsa, USA, 2011.
[7] Maher, M.J., S.A. Rego, and G.M. Asnis, Sleep disturbances in patients with post-
traumatic stress disorder: epidemiology, impact and approaches to management. CNS
Drugs, 2006. 20(7): 567–590.
[8] American Psychiatric Association, Diagnostic and statistical manual of mental disor-
ders, 4th ed., text rev., American Psychiatric Association, Washington, DC, 2000.
[9] Ponniah, K. and S. Hollon, Empirically supported psychological treatments for adult
acute stress disorder and posttraumatic stress disorder: a review. Depress Anxiety, 2009.
26(12): 1086–1109.
[10] Stein, D.J., J.C. Ipser, and S. Seedat, Pharmacotherapy for post traumatic stress disorder
(PTSD). Cochrane Database Syst Rev, 2006(1): p. CD002795
[11] Belleville, G., et al., The impact of cognitive-behavior therapy for anxiety disorders on
concomitant sleep disturbances: a meta-analysis. J Anxiety Disord, 2010. 24(4): 379–386.
[12] Galovski, T.E., et al., Does cognitive-behavioral therapy for PTSD improve perceived
health and sleep impairment? J Trauma Stress, 2009. 22(3): 197–204.
[13] Krakow, B. and A. Zadra, Clinical management of chronic nightmares: imagery
rehearsal therapy. Behav Sleep Med, 2006. 4(1): 45–70.
[14] Lydiard, R.B. and M.H. Hamner, Clinical importance of sleep disturbance as a treat-
ment target in PTSD. Focus, 2009. VII(2): 176–183.
[15] Aurora, R.N., et al., Best practice guide for the treatment of nightmare disorder in
adults. J Clin Sleep Med, 2010. 6(4): 389–401.
A Multidimensional Approach to Post-Traumatic Stress Disorder - from Theory to Practice222
[16] Aurora, R.N., et al., Revisiting evidence-based guidelines: not such a nightmare
standards of practice committee. J Clin Sleep Med, 2011. 7(5): 554–556.
[17] Hudson, S.M., et al., Prazosin for the treatment of nightmares related to posttraumatic
stress disorder: a review of the literature. Prim Care Companion CNS Disord, 2012.
14(2). doi: 10.4088/PCC.11r01222
[18] Zadra, A. and R.O. Pihl, Lucid dreaming as a treatment for recurrent nightmares.
Psychother Psychosom, 1997. 66(1): 50–55.
[19] Lerner, F. and J.L. Hamblen, Surveying the traumatic stress literature: the effective use
of bibliographic databases in preparing reviews and meta-analyses. J Trauma Stress,
2010. 23(6): 819–822.
[20] Belleville, G., et al., Meta-analytic review of the impact of cognitive-behavior therapy
for insomnia on concomitant anxiety. Clin Psychol Rev, 2011. 31(4): 638–652.
[21] Altman, D.G., et al., The revised CONSORT statement for reporting randomized trials:
explanation and elaboration. Ann Intern Med, 2001. 134(8): 663–694.
[22] Boynton, L., et al., Preliminary findings concerning the use of prazosin for the treatment
of posttraumatic nightmares in a refugee population. J Psychiatr Pract, 2009. 15(6): 454–
459.
[23] Calohan, J., et al., Prazosin treatment of trauma nightmares and sleep disturbance in
soldiers deployed in Iraq. J Trauma Stress, 2010. 23(5): 645–648.
[24] Peskind, E.R., et al., Prazosin reduces trauma-related nightmares in older men with
chronic posttraumatic stress disorder. J Geriatric Psychiatry Neurol, 2003. 16(3): 165–171.
[25] Raskind, M.A., et al., Prazosin reduces nightmares in combat veterans with posttrau-
matic stress disorder. J Clini Psychiatry, 2002. 63(7): 565–568.
[26] Raskind, M.A., et al., Reduction of nightmares and other PTSD symptoms in combat
veterans by prazosin: a placebo-controlled study. Am J Psychiatry, 2003. 160(2): p. 371-3.
[27] Raskind, M.A., et al., A parallel group placebo controlled study of prazosin for trauma
nightmares and sleep disturbance in combat veterans with post-traumatic stress
disorder. Biol Psychiatry, 2007. 61(8): 928–934.
[28] Taylor, F.B., et al., Prazosin effects on objective sleep measures and clinical symptoms
in civilian trauma posttraumatic stress disorder: a placebo-controlled study. Biol
Psychiatry, 2008. 63(6): 629–632.
[29] Thompson,  C.E.,  et  al.,  Nonnightmare  distressed  awakenings  in  veterans  with
posttraumatic  stress  disorder:  response  to  prazosin.  J  Trauma  Stress,  2008.  21(4):
417–420.
[30] Cook, J., et al., Imagery rehearsal for posttraumatic nightmares: a randomized control-
led trial. J Trauma Stress, 2010. 23(5): 553–563.
The Impact of Cognitive-Behavioral Therapies for Nightmares and Prazosin on the Reduction of Post-Traumatic...
http://dx.doi.org/10.5772/64224
223
[31] Davis, J.L. and D.C. Wright, Case series utilizing exposure, relaxation, and rescripting
therapy: impact on nightmares, sleep quality, and psychological distress. Behav Sleep
Med, 2005. 3(3): 151–157.
[32] Davis, J.L. and D.C. Wright, Randomized clinical trial for treatment of chronic night-
mares in trauma-exposed adults. J Trauma Stress, 2007. 20(2): 123–133.
[33] Davis, J.L., et al., Physiological predictors of response to exposure, relaxation, and
rescripting therapy for chronic nightmares in a randomized clinical trial. J Clin Sleep
Med, 2011. 7(6): 622–631.
[34] Forbes, D., A. Phelps, and T. McHugh, Treatment of combat-related nightmares using
imagery rehearsal: a pilot study. J Trauma Stress, 2001. 14(2): 433–442.
[35] Germain, A. and T. Nielsen, Impact of imagery rehearsal treatment on distressing
dreams, psychological distress, and sleep parameters in nightmare patients. Behav
Sleep Med, 2003. 1(3): 140–154.
[36] Germain, A., et al., Placebo-controlled comparison of prazosin and cognitive-behavio-
ral treatments for sleep disturbances in US Military Veterans. J Psychosom Res, 2012.
72(2): 89–96.
[37] Harb, G.C., et al., Post-traumatic stress disorder nightmares and sleep disturbance in
Iraq war veterans: A feasible and promising treatment combination. J Aggression
Maltreatment Trauma, 2009. 18(5): 516–531.
[38] Krakow, B., et al., An open-label trial of evidence-based cognitive behavior therapy for
nightmares and insomnia in crime victims with PTSD. Am J Psychiatr, 2001. 158(12):
2043–2047.
[39] Krakow, B., et al., A controlled study of imagery rehearsal for chronic nightmares in
sexual assault survivors with PTSD: a preliminary report. J Trauma Stress, 2000. 13(4):
589–609.
[40] Krakow, B., et al., Imagery rehearsal therapy for chronic nightmares in sexual assault
survivors with posttraumatic stress disorder: a randomized controlled trial. JAMA,
2001. 286(5): 537–545.
[41] Lancee, J., J. van den Bout, and V.I. Spoormaker, Expanding self-help Imagery Rehearsal
Therapy for nightmares with sleep hygiene and lucid dreaming: a waiting-list control-
led trial. Int J Dream Res, 2010. 3(2): 111–120.
[42] Lu, M., et al., Imagery rehearsal therapy for posttraumatic nightmares in U.S. veterans.
J Trauma Stress, 2009. 22(3): 236–239.
[43] Nappi, C.M., et al., Effectiveness of imagery rehearsal therapy for the treatment of
combat-related nightmares in veterans. Behav Ther, 2010. 41(2): 237–244.
[44] Swanson, L.M., et al., A combined group treatment for nightmares and insomnia in
combat veterans: a pilot study. J Trauma Stress, 2009. 22(6): 639–642.
A Multidimensional Approach to Post-Traumatic Stress Disorder - from Theory to Practice224
[45] Thunker, J. and R. Pietrowsky, Effectiveness of a manualized imagery rehearsal therapy
for patients suffering from nightmare disorders with and without a comorbidity of
depression or PTSD. Behav Res Ther, 2012. 50(9): 558–564.
[46] Ulmer, C.S., J.D. Edinger, and P.S. Calhoun, A multi-component cognitive-behavioral
intervention for sleep disturbance in veterans with PTSD: a pilot study. J Clin Sleep
Med, 2011. 7(1): 57–68.
[47] Borenstein, M., et al., eds. Introduction to meta-analysis, John Wiley and Sons, Chi-
chester, UK, 2009.
[48] Comprehensive Meta-Analysis [Computer software]. (2012). Englewood, NJ: Biostat.
Available from http://www.comprehensive.com
[49] Blake, D., et al., The development of a Clinician-Administered PTSD Scale. J Trauma
Stress, 1995. 8(1): 75–90.
[50] Sundin, E.C. and M.J. Horowitz, Impact of event scale: psychometric properties. Br J
Psychiatry, 2012. 180: 205–209.
[51] Weathers, F., T. Keane, and J. Davidson, Clinician-administered PTSD scale: a review
of the first ten years of research. Depress Anxiety, 2001. 13(3): 132–156.
[52] Foa, E.B., et al., Reliability and validity of a brief instrument for assessing post-traumatic
stress disorder. J Trauma Stress, 1993. 6(4): 459–473.
[53] Foa, E.B., ed. Posttraumatic stress diagnostic scale manual, National Computer Systems
Inc., Minneapolis, MN, 1995.
[54] Buysse, D.J., et al., The Pittsburgh sleep quality index: a new instrument for psychiatric
practice and research. Psychiatry Res, 1989. 28(2): 193–213.
[55] Morin, C.M., Insomnia. Psychological assessment and management, Guilford Press,
New York, 1993.
[56] Higgins, J.P., et al., Measuring inconsistency in meta-analyses. BMJ, 2003. 327(7414):
557–560.
[57] Huedo-Medina, T.B., et al., Assessing heterogeneity in meta-analysis: Q statistic or I2
index? Psychol Methods, 2006. 11(2): 193–206.
[58] Sterne, J. and R. Harbord, Funnel plots in meta-analysis. The Stata Journal, 2004.
4(Number 2): 127–141.
[59] Orwin, R.G., A fail-safe N for effect size in meta-analysis. J Educ Stat, 1983. 8(2): 157–
159.
[60] Davis, J.L. and D.C. Wright, Case series utilizing exposure, relaxation, and rescripting
therapy: impact on nightmares, sleep quality, and psychological distress. Behav Sleep
Med, 2005. 3(3): 151–157.
The Impact of Cognitive-Behavioral Therapies for Nightmares and Prazosin on the Reduction of Post-Traumatic...
http://dx.doi.org/10.5772/64224
225
[61] Ross, R.J., et al., Sleep disturbance as the hallmark of posttraumatic stress disorder. Am
J Psychiatry, 1989. 146(6): 697–707.
[62] Dierks, M.R., J.K. Jordan, and A.H. Sheehan, Prazosin treatment of nightmares related
to posttraumatic stress disorder. Ann Pharmacother, 2007. 41(6): 1013–1017.
[63] Foa, E.B., T.M. Keane, and M.J. Friedman, Effective treatments for PTSD. Practice
guidelines from the international society for traumatic stress studies, 2nd ed., Guilford
Publications, Inc., New York, 2008.
[64] Raskind, M.A., et al., A parallel group placebo controlled study of prazosin for trauma
nightmares and sleep disturbance in combat veterans with post-traumatic stress
disorder. Biol Psychiatry, 2007. 61(8): 928–934.
[65] Ahmadpanah, M., et al., Comparing the effect of prazosin and hydroxyzine on sleep
quality in patients suffering from posttraumatic stress disorder. Neuropsychobiology,
2014. 69(4): 235–242.
[66] Balliett, N.E., J.L. Davis, and K.E. Miller, Efficacy of a brief treatment for nightmares
and sleep disturbances for veterans. Psychol Trauma, 2015. 7(6): 507–515.
[67] Margolies, S.O., et al., Efficacy of a cognitive-behavioral treatment for insomnia and
nightmares in Afghanistan and Iraq veterans with PTSD. J Clin Psychol, 2013. 69(10):
1026–1042.
[68] Raskind, M.A., et al., A trial of prazosin for combat trauma PTSD with nightmares in
active-duty soldiers returned from Iraq and Afghanistan. Am J Psychiatry, 2013. 170(9):
1003–1010.
[69] Ho, F.Y., C.S. Chan, and K.N. Tang, Cognitive-behavioral therapy for sleep disturbances
in treating posttraumatic stress disorder symptoms: a meta-analysis of randomized
controlled trials. Clin Psychol Rev, 2016. 43: 90–102.
[70] Khachatryan, D., et al., Prazosin for treating sleep disturbances in adults with post-
traumatic stress disorder: a systematic review and meta-analysis of randomized
controlled trials. Gen Hosp Psychiatry, 2016. 39: 46–52.
[71] Stickgold, R. and M.P. Walker, Memory consolidation and reconsolidation: what is the
role of sleep? Trends Neurosci, 2005. 28(8): 408–415.
[72] Walker, M.P., The role of sleep in cognition and emotion. Ann N Y Acad Sci, 2009. 1156:
168–197.
[73] Stickgold, R., Of sleep, memories and trauma. Nat Neurosci, 2007. 10(5): 540–542.
[74] Casement, M.D. and L.M. Swanson, A meta-analysis of imagery rehearsal for post-
trauma nightmares: effects on nightmare frequency, sleep quality, and posttraumatic
stress. Clin Psychol Rev, 2012. 32(6): 566–574.
A Multidimensional Approach to Post-Traumatic Stress Disorder - from Theory to Practice226
[75] Escamilla, M., et al., Management of post-traumatic nightmares: a review of pharma-
cologic and nonpharmacologic treatments since 2010. Curr Psychiatry Rep, 2012. 14(5):
529–535.
[76] Nappi, C.M., S.P. Drummond, and J.M. Hall, Treating nightmares and insomnia in
posttraumatic stress disorder: a review of current evidence. Neuropharmacology, 2012.
62(2): p. 576-85.
[77] Harb, G.C., et al., A critical review of the evidence base of imagery rehearsal for
posttraumatic nightmares: pointing the way for future research. J Trauma Stress, 2013.
26(5): 570–579.
[78] Augedal, A.W., et al., Randomized controlled trials of psychological and pharmaco-
logical treatments for nightmares: a meta-analysis. Sleep Med Rev, 2012. 6(12): 00071–
00078.
[79] Germain, A., et al., Effects of a brief behavioral treatment for PTSD-related sleep
disturbances: a pilot study. Behav Res Ther, 2007. 45(3): 627–632.
[80] Nielsen, T. and R. Levin, Nightmares: a new neurocognitive model. Sleep Med Rev,
2007. 11(4): 295–310.
[81] Robert, G. and A. Zadra, Measuring nightmare and bad dream frequency: impact of
retrospective and prospective instruments. J Sleep Res, 2008. 17(2): 132–139. doi:
10.1111/j.1365-2869.2008.00649.x.
The Impact of Cognitive-Behavioral Therapies for Nightmares and Prazosin on the Reduction of Post-Traumatic...
http://dx.doi.org/10.5772/64224
227

